

TEAR HERE


PLEASE FILL IN BLOCK LETTERS

TEAR HERE

COMMON BID CUM APPLICATION FORM

AAKAAR MEDICAL TECHNOLOGIES LIMITED - INITIAL PUBLIC OFFER - R
Registered Office: 801, Heritage Plaza, Telli Galli Cross Road, Andheri (East), Mumbai-400069, Maharashtra, India.
Corporate Identity Number: U74900MH2013PLC244717
Contact Person: Anoopkumar Vishwanathan Pillai, Company Secretary and Compliance Officer; Tel: +91 84528 44024
E-mail: companysecretary@akaarmedical.in; Website: www.akaarmedical.in

FOR RESIDENT INDIAN INVESTORS INCLUDING
RESIDENT QIBs, NON-INSTITUTIONAL BIDDERS,
RETAIL INDIVIDUAL BIDDERS AND ELIGIBLE NRIs
APPLYING ON A NON-REPATRIATION BASIS

**To,**
The Board of Directors
AAKAAR MEDICAL TECHNOLOGIES LIMITED

100% BOOK BUILT OFFER
ISIN : INE1GYP01013

Bid cum Application Form No.

MEMBERS OF THE SYNDICATE STAMP & CODE	SUB-SYNDICATE MEMBER/ REGISTERED BROKER SCSB/CDP/RTA STAMP & CODE
SUB-BROKER'S / SUB-AGENT'S STAMP & CODE	SCSB BRANCH STAMP & CODE
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.

1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER
Mr./Ms./M/s.
Address
Email
Tel. No. (with STD code) / Mobile

2. PAN OF SOLE / FIRST BIDDER

3. BIDDER'S DEPOSITORY ACCOUNT DETAILS ☐ NSDL ☐ CDSL
For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID

4. BID OPTIONS (ONLY RETAIL INDIVIDUAL BIDDERS CAN BID AT "CUT-OFF")

Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of 1,600 Equity Shares)	Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1 only) (In Figures only)																	
		Bid Price			Retail Discount			Net Price			"Cut-off" (Please ✓ tick)								
		8	7	6	5	4	3	2	1	3		2	1	3	2	1			
Option 1																			
(OR) Option 2																			
(OR) Option 3																			

5. CATEGORY
☐ Retail Individual Bidder
☐ Non-Institutional Bidder
☐ QIB

6. INVESTOR STATUS
☐ Individual(s) - IND
☐ Hindu Undivided Family - HUF*
☐ Bodies Corporate - CO
☐ Systemically Important NBFCs
☐ Banks & Financial Institutions - FI
☐ Mutual Funds - MF
☐ National Investment Fund - NIF
☐ Insurance Funds - IF
☐ Insurance Companies - IC
☐ Venture Capital Fund - VCF
☐ Alternative Investment Fund - AIF
☐ Other QIBs - OTH
☐ Non Resident Indian - NRI (Non-repatriation basis)
☐ All entities other than QIBs, Bodies Corporate and Individuals - NOH
Please Specify
*HUF should apply only through Karta (Application by HUF would be treated on par with individual).


7. PAYMENT DETAILS [IN CAPITAL LETTERS]
Amount blocked (₹ in figures) (₹ in words)
ASBA Bank A/c No.
Bank Name & Branch
OR
UPI ID (Maximum 45 characters)

PAYMENT OPTION : FULL PAYMENT ☒

8A. SIGNATURE OF SOLE/ FIRST BIDDER
Date : , 2025

**8B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S)
(AS PER BANK RECORDS)**
I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer.
1)
2)
3)

MEMBERS OF THE SYNDICATE / SUB-SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA / AGENT STAMP (Acknowledging upload of Bid in Stock Exchange system)

**AAKAAR MEDICAL TECHNOLOGIES LIMITED**
INITIAL PUBLIC OFFER - R

Acknowledgement Slip for Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent

Bid cum Application Form No.

PAN of Sole / First Bidder

Stamp & Signature of SCSB Branch

Amount blocked (₹ in figures) **ASBA Bank A/c No./UPI ID**
Bank Name & Branch
Received from Mr./Ms./M/s.
Telephone / Mobile **Email**

Stamp & Signature of Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent
Name of Sole / First Bidder
Acknowledgement Slip for Bidder
Bid cum Application Form No.

AAKAAR MEDICAL TECHNOLOGIES LIMITED - INITIAL PUBLIC OFFER - R

	Option 1	Option 2	Option 3
No. of Equity Shares			
Bid Price (₹)			
Amount Blocked (₹ in figures)			
ASBA Bank A/c No./UPI ID			
Bank Name & Branch			

Important Note : Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected.

AAKAAR MEDICAL TECHNOLOGIES LIMITED

1

P. Oritent press limited, Tel: 022-4285888

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS DATED JUNE 14, 2025 (THE "RHP"). YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE RHP.

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID CUM APPLICATION FORM

(IN CASE OF A JOINT BID, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST BIDDER WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL JOINT BIDDERS. THE FIRST BIDDER SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE OFFER OF EQUITY SHARES.)

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. On the basis of the Red Herring Prospectus dated June 14, 2025, filed with the Registrar of Companies, Maharashtra at Mumbai, I/We hereby confirm that I am/we are eligible person(s) to invest in the Offer in accordance with applicable laws. The amount payable on Bidding has been blocked in the ASBA Account with the relevant SCSE or the bank account linked with the UPI ID (in case of UPI Bidders using UPI Mechanism) as mentioned in this Bid cum Application Form, as the case may be. I/We agree to accept the Equity Shares Bid for, or such lesser number as may be Allotted to me/us subject to the terms of the RHP, Abridged Prospectus, the GID, the Bid cum Application Form and other applicable laws. I/We undertake that I/We will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be Allotted and to register my/our address as given in the Depository records and to place my/our name on the register of members of the Company. I/We acknowledge that in case of QIB Bidders, only the SCSEs (for Bids other than the Bids by Anchor Investors), and the BRLM and its affiliated Syndicate Member (only in the Specified Locations) have the right to reject Bids (including on technical grounds) at the time of acceptance of Bid cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, whereas it has a right to reject it from Non-Institutional Bidders and Retail Individual Bidders based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP as applicable. I/We authorise the Company to make the necessary changes in this Bid cum Application Form and the RHP for the filing of the Prospectus with the RoC without intimation to me/us and use this Bid cum Application Form as the application form for the purpose of the Offer. I/We confirm that I/We have read the RHP. My / our investment decision is solely based on the RHP as applicable and the Prospectus.

I/WE CONFIRM THAT: EITHER I am/we are Indian national(s) resident in India and I am/we are not applying for the said Equity Shares as nominees of any person resident outside India or foreign nationals or I am/we are Indian national(s) resident in India and I am/we are applying for the said Equity Shares as power of attorney holder(s) of non-resident Indian(s) as mentioned on non-repatriation basis OR I am/we are Indian national(s) resident outside India and I am/we are applying for the said Equity Shares on my/our own behalf through NRO account on non-repatriation basis. I/We represent, warrant, acknowledge and agree with the Company and the BRLM as follows: (A) I/We have read the RHP and that my/our investment decision is based solely on the RHP (B) I/We have read and agree to the representations, warranties and agreements contained in the section "Other Regulatory and Statutory Disclosures-Disclaimer in respect of Jurisdiction" in the RHP (C) the Equity Shares offered in the Offer have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state of the United States and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws and that the Equity Shares are being offered and sold only outside the United States in accordance with Regulation S under the Securities Act; (D) I was/were outside of the United States at the time the Offer of the Equity Shares was made to me/us and I am/we are outside the United States at the time I/We signed this Bid cum Application Form; (E) the Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction; (F) I am/we are purchasing the Equity Shares pursuant to the laws of the jurisdictions applicable to me/us; (G) I am/we are not an affiliate of the Company or a person acting on behalf of such affiliate; (H) if I/we are making an application to acquire any of the Equity Shares as fiduciary or agent for one or more investor accounts, I/we have sole investment discretion with respect to each such account and I/we have full power to make the foregoing representations, warranties, acknowledgments and agreements on behalf of each such account; and (I) if I/we are making an application to acquire any of the Equity Shares for one or more managed accounts, I am /we are authorized in writing by each such managed account to subscribe to the Equity shares for each such managed account and to make (and I/we hereby make) the representations, warranties, acknowledgments and agreements herein for and on behalf of each such account, reading the reference to "I/we" to include such accounts.

FOR QIB BIDDERS: We confirm that the Bid size/maximum Equity Shares applied for by us does not exceed the relevant regulatory approvals/limits. We are not prohibited from accessing capital markets under any order/ruling/judgment of any regulatory, judicial or any other authority, including Securities and Exchange Board of India ("SEBI") or under the provisions of any law, regulation or statute.

Further: 1) In accordance with ASBA process provided in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and as disclosed in the RHP, I/we authorise (a) the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSEs (at Designated SCSEs Branches) or the RTAs (at the Designated RTA Locations) or the CDPs (at Designated CDP Locations), as the case may be, to do all acts as are necessary to make the application in the Offer, including uploading our Bid, blocking, unblocking of funds in the bank account of the applicant maintained with the SCSE as specified in the Bid cum Application Form or in the bank account of the Applicant linked with the UPI ID provided in the Bid cum Application Form, as the case may be, to transfer of funds to the Public Offer Account on receipt of instruction from Registrar to the Offer or the Sponsor Bank, as the case may be, after finalisation of Basis of Allotment; and (b) the Registrar to the Offer or Sponsor Bank, as the case may be, to issue instruction to the SCSEs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. 2) In case the amount available in the specified bank account is insufficient as per the highest Bid option, the SCSE/Registrar to the Offer shall reject the application. 3) I/We hereby authorise the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCSEs (at Designated SCSEs Branches) or CDPs (at Designated CDP locations) or the RTAs (at Designated RTA locations), as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band.

I/We hereby provide our consent to the Stock Exchange / Sponsor Bank / NPCI / Registrar to the Offer for collecting, storing and usage validating our PAN details from the bank account where my / our amount is blocked by the relevant SCSEs.

I/We acknowledge that as per existing policy of the Government of India, OCBs cannot participate in the Offer. I am/We are not an OCB. For further details, see "Issue Procedure" and "Restriction on Foreign Ownership of Indian Securities" beginning on pages 285 and 320, respectively of the RHP.

INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM

- Name of sole/ First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, only the name of the First Bidder (which should also be the first name in which the beneficiary account is held) should be provided in the Bid cum Application Form. The Bid means an 'indication to make an offer' during the Bid Offer period by a Bidder and not 'an offer'.
- The First Bidder, should mention his/ her PAN allotted under the Income Tax Act, 1961, DP ID, Client ID and UPI ID (as applicable). Except for Bids by or on behalf of the Central or State Government and the officials appointed by the courts and by investors who are exempt from the requirement of obtaining/ specifying their PAN for transacting in the securities market and by persons residing in the state of Sikkim, the Bidders, or in the case of Bid in joint names, the First Bidder (the first name under which the beneficiary account is held), should mention his/ her PAN allotted under the Income Tax Act, 1961. Any Bid cum Application Form without the PAN is liable to be rejected other than as specified above. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with Central Board of Direct Taxes ("CBDT") notification dated February 13, 2020 and press release dated June 25, 2021.
- Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar to the Offer will obtain Demographic Details registered with Depository Participants to be used, among other things, for Allotment, technical rejections or unblocking ASBA Account. Hence, Bidders are advised to immediately update any change in their Demographic Details as appearing on the records of the Depository Participant to ensure accuracy of records. Please note that failure to do so could result in failure in Allotment and delays in unblocking of ASBA Account at the Bidders' sole risk and neither the Members of the Syndicate nor the Registered Brokers nor the Registrar to the Offer nor RTAs/CDPs nor the SCSEs nor the Company shall have any responsibility and undertake any liability for the same.
- Bid Lot and Price Band:** The Price Band and the minimum Bid Lot has been decided by our Company in consultation with the Book Running Lead Manager. Price Band is ₹ 68/- to ₹ 72/- per Equity Share. The floor price is 6.8 times of the face value and the cap price is 7.2 times of the face value. Minimum Bid Lot is 1,600 Equity Shares and in multiples of 1,600 Equity Shares thereafter. The Bid Offer period shall be for a minimum of 3 Working Days and shall not exceed 10 Working Days. In case of revision of the Price Band the Bid Offer Period will be extended for at least three additional working days subject to the total Bid Offer Period not exceeding 10 working days. Any revision in the Price Band and the revised Bid Offer Period, if applicable, will be widely disseminated by notification to the Stock Exchange, by issuing a press release and also by indicating the changes on the websites of the BRLM and on the terminals of the Syndicate Members.
- Maximum and Minimum Bid Size:** In case of Retail Individual Bidders, such number of Equity Shares such that the Bid Amount does not exceed ₹ 200,000. Bids at the Cut-Off Price indicate their agreement to purchase the Equity Shares at the Offer Price, as determined at the completion of the Book Building Process. In case of Non-Institutional Bidders and QIB Bidders, the minimum Bid size shall be such number of Equity Shares in multiples of the minimum Bid Lot such that Bid Amount exceeds ₹ 200,000. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws and mentioned in the RHP.
- Please tick category as applicable to ensure proper upload of Bid in Stock Exchange system.
- Please tick investor status as applicable. Please ensure investor status is updated in your Depository records.
- Cheques/Demand Draft/Cash/stock invest/money orders/postal orders will not be accepted.** Eligible NRIs bidding on a non-repatriation basis by using the Resident Bid cum Application Form are required to authorise their SCSE to confirm or accept the UPI Mandate Request (in case of UPI Bidders Bidding through the UPI Mechanism), block their Non-Resident Ordinary (NRO) Accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. All Bidders including the Eligible NRIs Bidding on a non-repatriation basis can obtain the Bid cum Application Form from the Registered and Corporate Office of the Company or from any of the Members of the Syndicate or CDPs or RTAs or Registered Brokers from the Bidding Centers. In accordance with applicable law and SEBI UPI Circulars, Bidders to please ensure that SCSE where the ASBA Account is maintained has notified at least one branch in the location where Bid cum Application Forms will be deposited by Designated Intermediaries.
- Please note that application made using third party UPI ID or third party ASBA Bank Account are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply. UPI Bidders applying up to Rs. 500,000 shall apply through UPI mode as per NPCI vide circular reference no. NPCI/UI/OC No. 127/2021-22 dated December 09, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
 - UPI Bidders using UPI Mechanism:**
 - Please ensure that your bank is offering UPI facility for public offers.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Bidders Bidding using the UPI Mechanism may apply through the SCSEs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmid=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to ensure with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
 - UPI Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Offer Procedure" on page 285 of the RHP.
- Only the First Bidder is required to sign the Bid cum Application Form (Revision Form). Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Account holder is mandatory. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the account holder. Necessary revisions in the Bidders' undertaking and instructions will be required depending upon the jurisdiction in which the sale of shares is proposed.
- Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Members of the Syndicate, Registered Broker, CDPs, RTAs, and/or SCSEs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms; and c. Ensure that all applicable documents in support of the Bid are attached with the Bid cum Application Form.
- The Bidders may note that in case the DP ID, Client ID and PAN mentioned in the Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchange do not match with the DP ID, Client ID and PAN available in the Depository database, the Bid cum Application Form is liable to be rejected. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021. You may send the RHP and the Prospectus either in physical form or electronic form or both. You shall not distribute or forward this documents and these documents are subject to the disclaimers and restrictions contained in or accompanying in it.
- The Equity Shares have not been and will not be registered under the U.S. Securities Act 1933, as amended (the "Securities Act") or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, "U.S. persons" (as defined in Regulation S of the Securities Act), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Accordingly, the Equity Shares will be offered and sold (i) in the United States only to "qualified institutional buyers", as defined in Rule 144A of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S under the Securities Act and in compliance with the applicable laws of the jurisdiction where those offers and sales occur.
- This Bid cum Application Form is being offered to you on the basis that you (i) confirm that the representations, warranties, agreements and acknowledgement set out in "Other Regulatory and Statutory Disclosures" and "Issue Procedure" on pages 261 and 285 respectively of the RHP and (ii) agree to abide by (1) this Bid cum Application Form and (2) the RHP (if you are in India) or the Preliminary Offering Memorandum (if you are outside India) together with the terms and conditions contained therein.


Note: Terms used but not defined herein shall have the meaning assigned to such terms in the RHP. For detailed instructions for filling the various fields of this Bid cum Application Form, please refer to the GID, which is also available on the respective websites of the BRLM and the Stock Exchange.

TEAR HERE

- In case of queries related to Allotment/ credit of Allotted Equity Shares, the Bidders should contact Registrar to the Offer.
- In case of Bids submitted to the SCSEs, the Bidders should contact the relevant SCSE.
- In case of queries related to upload of Bids submitted to the relevant Members of the Syndicate / RTAs/ Registered Brokers / CDPs, as applicable, the Bidders should contact the relevant Designated Intermediary.
- For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and Mail id: ipo@npci.org.in and the Registrar to the Offer at Tel.: +91 22 62638200 and E-mail: ipo@bigshareonline.com
- In case of ASBA Bidders (other than 3-in-1 Bids) for a bid above INR 5,00,000, ensure that the bid is uploaded only by the SCSEs
- Ensure that you have accepted the UPI Mandate Request received from the Sponsor Bank prior to 5:00 p.m. of the Bid Offer Closing Date

COMPANY CONTACT DETAILS	REGISTRAR TO THE OFFER CONTACT DETAILS
AAKAAR MEDICAL TECHNOLOGIES LIMITED Registered Office: 801, Heritage Plaza, Telli Galli Cross Road, Andheri (East), Mumbai-400069, Maharashtra, India. Corporate Identity Number: U74900MH2013PLC244717 Contact Person: Anoopkumar Vishwanathan Pillai, Company Secretary and Compliance Officer; Tel: +91 84528 44024 E-mail: companysecretary@akaarmedical.in; Website: www.akaarmedical.in	Bigshare Services Private Limited Office No. S6-2, 6th Floor, Pinnacle Business Park, next to Ahura Center, Mahakali Caves Road, Andheri East, Mumbai-400093 Telephone: +91 22 62638200 E-mail: ipo@bigshareonline.com Investor grievance email: investor@bigshareonline.com Website: www.bigshareonline.com Contact Person: Vinayak Morbale SEBI Registration No: INR000001385

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

 (Please scan this QR Code to view this RHP)	This is an abridged prospectus containing salient features of the Red Herring Prospectus dated June 14, 2024 (the “RHP”). You are encouraged to read greater details available in the RHP which is available on the website of the Stock Exchange (https://www.nseindia.com/companies-listing/corporate-filings-offer-documents), the Company (www.aakaarmedical.in) and the Book Running Lead Manager (“BRLM”) (www.indorient.in). Unless otherwise specified all capitalized terms used herein and not specifically defined bear the same meaning as ascribed to them in the RHP.
--	--

THIS ABRIDGED PROSPECTUS CONSISTS OF EIGHT PAGES. PLEASE ENSURE THAT YOU HAVE RECEIVED ALL THE PAGES.



AAKAAR MEDICAL TECHNOLOGIES LIMITED

Corporate Identity Number: U74900MH2013PLC244717; **Date of Incorporation:** June 20, 2013

Registered Office	Contact Person	Email and Telephone	Website
801, Heritage Plaza, Telli Galli Cross Road, Andheri (East), Mumbai - 400069, Maharashtra, India.	Anoopkumar Vishwanathan Pillai Company Secretary and Compliance Officer	E-mail: companysecretary@aakaarmedical.in Telephone: +91 84528 44024	www.aakaarmedical.in

PROMOTERS OF THE COMPANY: DILIP RAMESH MESWANI AND BINDI DILIP MESWANI

DETAILS OF OFFER TO PUBLIC

Type of Issue	Fresh Issue Size	OFS Size	Total Issue Size	Issue Under	Share Reservation			
					QIB	NII	RII	Market Maker
Fresh Issue	Up to 37,50,400 of face value ₹10 each aggregating up to ₹[●] lakhs	Nil	Up to 37,50,400 of face value ₹10 each aggregating up to ₹[●] lakhs	This issue is being made in terms of Regulation 229(2) of Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended.	Not more than 17,79,200 Equity Shares	Not less than 5,36,000 Equity Shares	Not less than 12,48,000 Equity Shares	Up to 1,88,800 Equity Shares

These equity shares are proposed to be listed on NSE Emerge (i.e. Emerge platform of National Stock Exchange of India Limited).

DETAILS OF OFFER FOR SALE, SELLING SHAREHOLDERS AND THEIR AVERAGE COST OF ACQUISITION – NOT APPLICABLE AS THIS IS A FRESH ISSUE OF EQUITY SHARES

Price Band, Minimum Bid Lot & Indicative Timelines	
Price Band*	Rs. 68/- to Rs. 72/- Per Equity Share of face value of Rs. 10/- each.
Minimum Bid Lot Size	For details of minimum bid lot size, please refer to price band advertisement published in two national daily newspapers (one each in English and in Hindi) with wide circulation and one daily regional newspaper with wide circulation at least two working days prior to the Bid / Issue Opening Date.
Anchor Portion Issue Opens/Closes on**	Thursday, June 19, 2025
Bid/ Issue Open On	Friday, June 20, 2025
Bid/ Issue Closes On	Tuesday, June 24, 2025
Finalization of Basis of Allotment	On or before Wednesday, June 25, 2025
Initiation of Refunds	On or before Thursday, June 26, 2025
Credit of Equity Shares to Demat	On or before Thursday, June 26, 2025

accounts of Allottees	
Commencement of trading of Equity Shares	On or before Friday, June 27, 2025

**For details of price band and Basis of Issue Price, please refer to price band advertisement and page 101 of RHP.*

***Our Company, in consultation with the BRLMs, consider participation by Anchor Investors in accordance with the SEBI (ICDR) Regulations. The Anchor Investor Bidding Date shall be one Working Day prior to the Bid/Issue Opening Date i.e. Thursday, June 19, 2025.*

WEIGHTED AVERAGE COST OF ACQUISITION OF ALL SHARES TRANSACTED[^] IN (I) LAST ONE (1) YEAR; (II) LAST EIGHTEEN (18) MONTHS AND (III) LAST THREE (3) YEARS PRECEDING THE DATE OF THIS RED HERRING PROSPECTUS

Period	Weighted average cost of acquisition (in ₹)	Cap Price is 'X' times the Weighted Average Cost of Acquisition**	Range of acquisition price: lowest price – highest price (in ₹)
Last one (1) year preceding the date of this Red Herring Prospectus	64.00	1.13	64.00-64.00
Last eighteen (18) months preceding the date of this Red Herring Prospectus	63.93	1.13	15.38-64.00
Last three (3) years preceding the date of this Red Herring Prospectus	63.93	1.13	15.38-64.00

As certified by M/s C B Mehta & Associates, Chartered Accountants pursuant to their certificate dated June 14, 2025.

***To be updated once the price band information is available*

RISKS IN RELATION TO THE FIRST ISSUE

This being the first public offer of the Equity Shares of our Company, there has been no formal market for the Equity Shares. The face value of each Equity Share is ₹ 10/-. The Floor Price, Cap Price and Issue Price as determined by our Company in consultation with the Book Running Lead Manager, on the basis of the assessment of market demand for the Equity Shares by way of the Book Building process, as stated under **“Basis for Issue Price”** on page 100 should not be considered to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares nor regarding the price at which the Equity Shares will be traded after Listing.

GENERAL RISK

Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue, including the risks involved. The Equity Shares in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of this Red Herring Prospectus. Specific attention of the investors is invited to **“Risk Factors”** beginning on page 28 of the Red Herring Prospectus.

PROCEDURE

You may obtain a physical copy of the Bid-cum-Application Form and the RHP from the stock exchange, syndicate members, registrar to the issue, share transfer agents, depository participants, stock brokers, underwriters, bankers to the issue, investors’ associations or Self Certified Syndicate Banks.

If you wish to know about processes and procedures applicable to this issue, you may request for a copy of the RHP and/or the General Information Document (GID) from the BRLM’s or download it from the website of the Stock Exchange i.e. www.nseindia.com and the BRLM at www.indorient.in

PRICE INFORMATION OF BRLM					
Sr. No.	Issue Name	Board	+/- % change in Price on closing price, [+/- % change in closing benchmark]- 30 th calendar days from listing*	+/- % change in Price on closing price, [+/- % change in closing benchmark]- 90 th calendar days from listing*	+/- % change in Price on closing price, [+/- % change in closing benchmark]- 180 th calendar days from listing*
1.	eMudhra Limited	Main	-1.52%[-4.27%]	40.66%[4.68%]	22.13%[12.48%]
2.	Techknowgreen Solutions Limited	SME	99.01%[-4.49%]	232.97%[7.54%]	119.77%[10.15%]
3.	New Jaisa Technologies Limited	SME	186.17%[1.61%]	194.79%[10.85%]	107.02%[14.92%]
4.	Canarys Automation Limited	SME	37.26%[-2.10%]	38.23%[8.59%]	5.81%[13.64%]
5.	Plada Infotech Services Limited	SME	-10.52%[-1.65%]	-10.21%[9.46%]	-39.48%[14.64%]
6.	Chatha Foods Limited	SME	73.21%[1.84%]	76.89%[5.95%]	109.82%[15.82%]
7.	Yash Highvoltage Limited	SME	75.75%[-3.28%]	1.85%[-4.94%]	NA
8.	EMA Partners India Limited	SME	0.36[-1.28]	-10.52%[5.36%]-	NA
9.	Grand Continent Hotels Limited	SME	30.18%1.90%	NA	NA
10.	ATC Energies System Limited	SME	-10.72%4.29%	NA	NA
Name of BRLM and contact details (telephone and email id) of each BRLM			Indorient Financial Services Limited		
Name of Market Makers			Alacrity Securities Limited		
Name of Registrar to the Offer and contact details (telephone and email id)			Bigshare Services Private Limited		
Name of Statutory Auditor			M/s C B Mehta & Associates, Chartered Accountants		
Name of Credit Rating Agency and the rating or grading obtained if any			Not Applicable		
Name of Debenture trustee, if any.			Not Applicable		
Non-Syndicate Registered Brokers			You can submit Bid cum Application Forms in the Issue to Non Syndicate Registered Brokers at the Non Syndicate Broker Centers. For further details, see section titled <i>“Issue Procedure”</i> beginning at page 285 of the RHP		
Details regarding website address(es)/ link(s) from which the investor can obtain list of registrar to issue and share transfer agents, depository participants and stock brokers who can accept application from investor (as applicable)			https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognised=yes		

PROMOTERS OF THE ISSUER COMPANY			
Sr. No.	Name	Individual/ Corporate	Experience & Educational Qualification
1	Dilip Ramesh Meswani	Individual	Dilip Ramesh Meswani is the Managing Director and also one of the Promoters of our Company. He has completed his degree of Bachelor of Science from University of Bombay. He has also completed his Post Diploma in Medical Electronics from Shri Bhagubhai Mafatlal Polytechnic, Mumbai. He possesses over 24 years of experience in the fields of Medical Aesthetics.
2	Bindi Dilip Meswani	Individual	Bindi Dilip Meswani is the Chairperson and Non-Executive Director of our Company. She has completed her degree of Master of Commerce from Maharaja Sayajirao University of Baroda. She possesses over 10 years of experience in the fields of Medical Aesthetics.

BUSINESS OVERVIEW AND STRATEGY

Company Overview: We are a medical aesthetic company dealing in a wide range of aesthetics & specialized cosmetic products & devices. Our product range includes both Own brands (domestically manufactured products & internationally manufactured devices) and Imported Brands (distribution of imported brands) from countries such as Korea, Spain, Italy, and Austria.

Product/Service Offering: Our company primarily is engaged in the medical aesthetics and cosmetic dermatology segment which is further divided into following sub segment:-

Professional skin care, Professional hair care range, Injectables & Contouring, Homecare for Hair & Skin, Aesthetic Devices & Device Consumables

Revenue segmentation by product/service offering

Product Segments	Financial Year 2024-25		Financial Year 2023-24		Financial Year 2022-23		CAGR Segment Wise %
	(₹ in Lakhs)	% Share	(₹ in Lakhs)	% Share	(₹ in Lakhs)	% Share	
Aesthetic Products							
Professional skin care	1,725.72	28.02	1,144.87	24.83	920.21	28.07	36.94
Professional hair care range	652.72	10.60	189.46	4.11	75.98	2.32	193.10
Injectables & Contouring	1,683.55	27.34	1,274.66	27.64	813.10	24.80	43.89
Homecare for Hair & Skin	1,241.58	20.16	820.86	17.80	545.62	16.64	50.85
Aesthetic Devices & Device Consumables**	854.72	13.88	1181.25	25.62	923.55	28.17	(3.80)
Total	6,158.28	100.00	4,611.10	100.00	3,278.46	100.00	37.05

Geographies Served: Maharashtra, Karnataka, Tamil Nadu, Telangana, Uttar Pradesh, Kerala, Delhi, Punjab, Haryana, Gujarat

Revenue segmentation by geographies

State	Financial Year 2024-25	% Share of Revenue from Operations (%)	Financial Year 2023-24	% Share of Revenue from Operations (%)	Financial Year 2022-23	% Share of Revenue from Operations (%)	Total	% Share of Revenue from Operations (%)
Maharashtra	965.55	15.68	887.28	19.24	653.67	19.94	2,506.50	17.84
Karnataka	703.98	11.43	597.62	12.96	362.06	11.04	1,663.66	11.84
Tamil Nadu	580.99	9.43	367.82	7.98	170.93	5.21	1,119.74	7.97
Telangana	550.96	8.95	394.87	8.56	212.61	6.49	1,158.44	8.25
Uttar Pradesh	485.53	7.88	278.13	6.03	245.71	7.49	1,009.37	7.19
Kerala	462.28	7.51	305.84	6.63	221.90	6.77	990.02	7.05
Delhi	418.29	6.79	312.95	6.79	243.05	7.41	974.29	6.94
Punjab	375.61	6.10	274.66	5.96	273.43	8.34	923.70	6.58
Haryana	345.00	5.60	298.61	6.48	190.35	5.81	833.96	5.94
Gujarat	261.45	4.25	159.83	3.47	128.65	3.92	549.93	3.91
Total Revenue From Key States	5,149.62	83.62	3877.61	84.10	2,702.36	82.42	11,729.61	83.50
Total Revenue from Operation	6,158.28	100.00	4,611.10	100.00	3,278.46	100.00	14,047.84	100.00

Key Performance Indicators:

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS
(₹ in lakhs, unless otherwise stated)

Particulars	Financial Year 2024-25	Financial Year 2023-24	Financial Year 2022-23
Revenue from Operations ⁽¹⁾	6158.28	4,611.10	3,278.4
EBITDA ⁽²⁾	973.69	499.89	352.8
EBITDA Margin ⁽³⁾ (%)	15.81	10.84	10.7
PAT ⁽⁴⁾	603.95	287.02	215.3
PAT Margin ⁽⁵⁾ (%)	9.81	6.22	6.5
Net Worth ⁽⁶⁾	2320.28	1252.56	956.5
Return on Net Worth ⁽⁷⁾ (%)	33.81	25.88	24.3
Return on Capital Employed ⁽⁸⁾ (%)	21.02	17.68	22.3
Revenue from own brands ⁽⁹⁾	2311.15	1393.65	774.4
Sales team ⁽¹⁰⁾ (Nos)	129	128	8
Number of Customers Billed ⁽¹¹⁾ (Nos)	5236	5,205	4,50

Client Profile or Industries Served: Medical Aesthetics and Cosmetic Dermatology Market

Revenue segmentation in terms of top 5/10 clients or Industries:

Customer Name	% of Revenue from Operations		
	FY 2024-25	FY 2023-24	FY 2022-23
% of Revenue from Top 10 Customers	8.16	10.96	14.88

Intellectual Property, if any

Our Company has registered a total of 38 trademarks with the Registrar of Trademarks and made application for registration of 5 trademarks under the Trademarks Act, 1999, which are objected as on date.

Market Share: Not ascertainable

Manufacturing plant, if any: N.A.

Employee Strength: As on May 30, 2025, the Company has employed 177 employees at various levels of the Organization.

WBOARD OF DIRECTORS				
Sr. No.	Name	Designation	Experience & Educational Qualification	Other Directorships
1.	Dilip Ramesh Meswani	Managing Director	He has completed his degree of Bachelor of Science from University of Bombay. He has also completed his Post Diploma in Medical Electronics from Shri Bhagubhai Mafatlal Polytechnic, Mumbai. He possesses over 24 years of experience in the fields of Medical Aesthetics.	Indian Companies Revigen Medicare Private Limited Foreign Companies Nil
2.	Rahul Babasaheb Sawakhande	CEO and Executive Director	He has completed his degree of Bachelor of Surgery and Medicine from Maharashtra University of Health Science, Nashik and a Diploma in Business Management from the Institute of chartered Financial Analyst of Indian University, Tripura. He holds over 15 years of experience in the fields of Dermatology and Medical Regulatory affairs.	Indian Companies Fatcutsweight Wellness (OPC) Private Limited. Foreign Companies Nil
3.	Bindi Dilip Meswani	Chairperson and Non-Executive Director	She has completed her degree of Master of Commerce from Maharaja Sayajirao University of Baroda. She possesses over 10 years of experience in the fields of Medical Aesthetics. She is also a director in Revigen Medicare Private Limited from June 14, 2013.	Indian Companies Revigen Medicare Private Limited Foreign Companies Nil
4.	Deepanjan Periwal	Independent Director	He qualified as a Chartered Accountant from the Institute of Chartered Accountants of India. He has also completed her Bachelor of Commerce from Nagpur University, He has also completed a certification course on Senior Management Programme from Indian Institute of Management, Ahmedabad. He possesses over 15 years of experience in the fields of Accounts and Finance.	Indian Companies Vyara Tiles Limited. Desert Landscape India Private Limited. RCRS Innovations Limited. City First Financial Advisor Private Limited Foreign Companies Nil
5.	Rajendra Indubhai Dhandhukia	Non-Executive Director	He has completed his degree of Bachelor of Science from University of Bombay, he has also completed Diploma in Marketing and Sales Management from Bhartiya Vidya Bhavan, Mumbai and also a Certified Practitioner of narrative coach by Dr David Drake. He possesses over 15 years of experience in the fields of Pharmaceutical Industry.	Indian Companies Nil Foreign Companies Nil

For further details in relation to our Board of Directors, see **“Our Management”** beginning on page 172 of the RHP.

OBJECTS OF THE OFFER

Details of means of finance –

Our Company proposes to utilize the Net Proceeds towards the following objects:

Particulars	Amount to be funded from Net Proceeds ⁽¹⁾	Estimated schedule of deployment of Net Proceeds in	
		Financial Year 2026 (in ₹ Lakhs)	Financial Year 2027 (in ₹ Lakhs)
Funding working capital requirements of our Company	2,035.00	935.00	1,100.00
General corporate purposes ⁽¹⁾	●	●	●
Net Proceeds	●	●	●

⁽¹⁾To be finalized upon determination of the Issue Price and updated in the Prospectus prior to filing with the ROC. The amount utilized for general corporate purposes shall not exceed 15% of the Gross Proceeds or ₹10 crore, whichever is lower.

Details and reasons for non-deployment or delay in deployment of proceeds or changes in utilization of

issue proceeds of past public issues / rights issue, if any, of the Company in the preceding 10 years: Nil

Name of monitoring agency, if any – Not Applicable

Terms of Issuance of Convertible Security, if any - Not Applicable

SHAREHOLDING PATTERN:

Sr. No.	Particulars	Pre Issue number of shares	% Holding of Pre issue
1.	Promoters and Promoter Group	94,96,513	91.12%
2.	Public	9,25,903	8.88%
	Total	1,04,22,416	100.00%

Number/amount of equity shares proposed to be sold by selling shareholders. – Not Applicable.

RESTATED FINANCIALS STATEMENT

A summary of the financial information of our Company as derived from the Restated Financial Statements as at financial years ended March 31, 2025 and March 31, 2024 and March 31, 2023 as follows:

(₹ in Lakhs)

Particulars	March 31, 2025	March 31, 2024	March 31, 2023
Total income from operations (Net)	6158.28	4,611.10	3,278.46
Net Profit/(Loss) before tax and extraordinary items	808.05	388.53	310.25
Net Profit / (Loss) after tax and extraordinary items	603.95	287.02	215.32
Equity Share Capital	1,042.24	70.00	70.00
Reserves and Surplus	1,278.04	1,184.16	896.07
Net worth	2320.28	1,252.56	965.54
Earnings per share (basic) (in ₹)	6.13	3.15	2.37
Earnings per share (diluted) (in ₹)	6.13	3.14	2.36
Return on net worth (%)	33.81%	25.88%	24.35%
Net Asset Value per Equity Share	22.26	13.76	10.61

For further details, see “*Financial Information*” beginning on page 196

INTERNAL RISK FACTORS

The below mentioned risks are top 5 risk factors as per the RHP.

- Our expansion into new product categories and an increase in the number of products offered by us may expose us to new challenges and more risks.
- We are also constantly looking to tie-up with reputed brands to distribute their products in India & we derive a majority revenue from these tie-ups which may expose us to various risks.
- We rely on third party contract manufacturers (domestic and international) & loan licensing partners for manufacturing products & devices which we sell under our own Brand. Our dependence on third-party manufacturers for the manufacturing of all our products subjects us to certain risks, which, if realized, could adversely affect our business, results of operations, cash flows and financial condition.
- Our registered office is situated in Maharashtra and we derive a significant portion of our revenue from state of Maharashtra & Karnataka, making us vulnerable to geographical concentration risk.
- We have appointed Parekh Integrated Services Private Limited (PISPL) as a CSA agent for storing, delivering and distributing our products & recovery of dues. Any non-performance or breach of covenants of the CSA agreement For further details on ‘*Risk Factors*’ please refer page no. 28 of the Red Herring Prospectus.

SUMMARY OF OUTSTANDING LITIGATIONS, CLAIMS AND REGULATORY ACTION

A summary of outstanding litigation proceedings involving our Company, our Promoters, Directors and our Group Company, as on the date of this Red Herring Prospectus as disclosed in the section titled “*Outstanding Litigation and Material Developments*” in terms of the SEBI (ICDR) Regulations and the Materiality Policy is provided below:

(₹ in lakhs)

Particulars	Criminal Proceedings	Tax Proceedings (direct and indirect tax)	Statutory or Regulatory Proceedings	Disciplinary actions by SEBI or Stock Exchanges against our Promoter	Material civil litigation	Aggregate amount involved^ (₹ in lakhs)
Company						
By our Company	1	NIL	NIL	NIL	1	42.99

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE PROSPECTUS

Against our Company	NIL	1	NIL	NIL	NIL	0.02
Director's						
By our Directors	NIL	NIL	NIL	NIL	NIL	NIL
Against our Directors	NIL	2	NIL	NIL	NIL	4.14
Promoter's						
By the Promoters	1	NIL	NIL	NIL	NIL	4.14
Against our Promoters	NIL	4	NIL	NIL	NIL	4.20
KMP & SMP						
By our KMP and SMP	NIL	NIL	NIL	NIL	NIL	NIL
Against our KMP and SMP	NIL	NIL	NIL	NIL	NIL	NIL

**To the extent quantifiable.*

Brief details of top 5 material outstanding litigations against the Company and amount involved, as applicable.

Sr. No.	Particulars	Amount Involved (₹ in Lakhs)
	Aakaar Medical Technologies Private Limited (“ Appellant/Opposite Party ”) has filed a First Appeal bearing number 919 of 2024 (“ Appeal ”) before the Hon’ble Telangana State Consumer Disputes Redressal Commission at Hyderabad (“ State Forum ”) against Radhika Reddy Galla (“ Respondent/ Complainant ”). The Appellant has filed the present Appeal against an impugned order dated July 26, 2024 (“ Impugned Order ”) passed by the Hon’ble District Consumer Disputes Redressal Commission at Hyderabad (“ District Forum ”) in Consumer Case bearing number 184 of 2023 wherein the Appellant has been ordered to pay refund ₹35,00,000 along with interest at the rate of 10% from June 30, 2024 till date of realization and take back the subject machine, ₹50,000 towards compensation and ₹10,000 towards costs. The Appellant contends that the Respondent does not fall under the definition of ‘Consumer’ under section 1(7) of the Consumer Protection Act and other material facts were looked away by the District Forum. Therefore, the present Appeal has been filed praying for setting aside the Impugned Order. The Appeal is presently pending and the next date of hearing is June 17, 2025.	35.60
	Dilip Ramesh Meswani on behalf of the Company (“ Complainant ”) filed a FIR bearing number 0476 of 2024 dated September 09, 2024 (“ FIR ”) before Andher Police Station against Vijesh Manshiker Jha (“ Accused ”) under section 408 and 420 of Bhartiya Dand Sanhita, 1860. Complainant states that the Accused was National Sales Head at his Company. Further, the Complainant alleges that the Accused had requested for Ajay Kumar to conduct all training and collection of money against all products sold by the Complainant’s Company and that the Accused had collected ₹7,39,000 for products sold from Ajay Kumar and had used the sales proceeds for his personal gain and never debited to the account of the Complainant’s Company. The Complainant alleges that the Accused had defrauded him and therefore, the present FIR is filed. The FIR is pending as on date.	7.39

Regulatory Action, if any - disciplinary action taken by SEBI or stock exchanges against the Promoters in last 5 financial years including outstanding action, if any - **NIL**

Brief details of outstanding criminal proceedings against Promoters– **NIL**

ANY OTHER IMPORTANT INFORMATION AS PER BRLM / ISSUER COMPANY - NIL

DECLARATION BY THE COMPANY

We hereby certify and declare that all relevant provisions of the Companies Act, 2013 and the rules, regulations and guidelines issued by the Government of India, and the regulations or guidelines issued by Securities and Exchange Board of India, established under Section 3 of the Securities and Exchange Board of India Act, 1992 as the case may be, have been complied with and no statement made in this Red Herring Prospectus is contrary to the provisions of the Companies Act, 2013, the Securities Contracts (Regulation) Act, 1956, and the Securities and Exchange Board of India Act, 1992, each as amended or the rules, regulations or guidelines issued thereunder, as the case may be. We further certify that all the disclosures and statements made in this Red Herring Prospectus are true and correct.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID REVISION FORM

I/We (on behalf of joint Bidders, if any) confirm that the Acknowledgement Slip for my/our Bids is enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in the Bid cum Application Form submitted earlier by me/us. I/We (on behalf of joint Bidders, if any) authorise you to reject this Bid Revision Form, in case any of the details of my/our existing Bids as appearing on the electronic book building system do not tally with the details given in this Bid Revision Form.

INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM

- Name of sole/ First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, the Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The Bid means an 'indication to make an offer' and not 'an offer'.
- Please ensure that the Bid options provided are in the same order as that provided in the Bid cum Application Form submitted earlier.
- In case there is no change in the particular Bid option, please write "NO CHANGE". In case you want to cancel the Bid option, please write "CANCELLED".
- Total Bid Amount payable must be calculated for the highest of three options, at Bid Price. Total Bid Amount to be paid must be calculated net of total amount paid at the time of submission of Bid cum Application Form. Bidders, please ensure that your bank has notified an SCSB Branch in the city where the Bid cum Application Form is being submitted.
- Revision of Bids in case of Revision of Price Band:** In case of an upward revision in the Price Band, Bidders who had Bid at Cut-off Price could either (i) revise their Bid or (ii) shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount plus additional payment does not exceed ₹ 200,000 if the Bidder wants to continue to Bid at Cut-off Price), with the SCSBs/ members of the Syndicate/Registered Brokers/RTA/CDPs to whom the original Bid was submitted. In case the total amount (i.e., original Bid Amount plus additional payment) exceeds ₹ 200,000, the Bid will be considered for allocation under the Non-Institutional Portion in terms of the RHP. If, however, the Bidder does not either revise the Bid or make additional payment and the Offer Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares Bid for, shall be adjusted downwards for the purpose of Allotment, such that no additional amount would be required to be blocked and the Bidder is deemed to have approved such revised Bid at Cut-off Price. In case of a downward revision in the Price Band, announced as above, UPI Bidders who have bid at Cut-off Price, could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
- Only the First Bidder is required to sign the Bid cum Application Form/Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Applicants should specify only his/her ASBA bank account or UPI ID linked with his/her own bank account in case of sole Bidder and ASBA bank account or UPI ID linked with the bank account of First Bidder in case of joint Bidder, in the application form. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the ASBA Account holder. Signature of the ASBA Account holder is mandatory.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply. Non-Institutional Bidders applying up to Rs. 500,000 can apply through UPI mode as per NPCI/UPI/OC No. 127/2021-22 dated December 09, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
 - UPI Bidders using UPI Mechanism:**
 - Please ensure that your bank is offering UPI facility for public offers.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlD=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmlD=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Offer through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
 - UPI Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Issue Procedure" on page 285 of the RHP.
- Other Instructions:** a. Revision to Bids must be made only in the prescribed Revision Form, as applicable; b. Revision Form must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Member of the Syndicate/ SCSBs/Registered Brokers/RTA/CDPs will not be liable for errors in data entry due to incomplete or illegible Revision Forms; c. Ensure that Acknowledgment Slip for your Bid and any other applicable documents in support of the revision are attached with the Revision Form; and d. Bidders shall only be required to Issue instruction to block the revised amount in excess of their original blocked amount based on the cap of the revised Price Band upon an upward revision of their Bid.
- Revision(s) in the Bid, the Bidders/Applicants will have to use the services of the same Designated Intermediary through which such Bidder/Applicant had placed the original Bid. Bidders/Applicants are advised to retain copies of the blank Revision Form and the Bid(s) must be made only in such Revision Form or copies thereof. Investors must ensure that their PAN is linked with Aadhaar card and are in compliance with the CBDT notification dated February 13, 2020 and press release dated June 25, 2021.

ISSUE STRUCTURE

Particulars ⁽²⁾	Market Maker Reservation Portion	QIBs ⁽¹⁾	Non-Institutional Bidders / Investors	Retail Individual Bidders / Investors
Number of Equity Shares available for Allotment/ allocation*	Upto 1,88,800 Equity Shares	Not more than 17,79,200 Equity Shares,	Not less than 5,36,000 Equity Shares available for allocation or Issue less allocation to QIBs and Retail Individual Bidders	Not less than 12,48,000 Equity Shares available for allocation or Issue less allocation to QIBs and Non-Institutional Bidders
Percentage of Issue Size available for Allotment/ allocation	5.04% of the Issue Size	Not more than 50% of the Net Issue being available for allocation to QIB Bidders. However, up to 5% of the Net QIB Portion will be available for allocation proportionately to Mutual Funds only. Mutual Funds participating in the Mutual Fund Portion will also be eligible for allocation in the remaining QIB Portion. The unsubscribed portion in the Mutual Fund Portion will be added to the Net QIB Portion	Not less than 15% of the Net Issue	Not less than 35% of the Net Issue.
Basis of Allotment ⁽³⁾	Firm Allotment	Proportionate as follows (excluding the Anchor Investor Portion): (a) Up to 36,800 Equity Shares shall be available for allocation on a proportionate basis to Mutual Funds only; and (b) Up to 7,12,000 Equity Shares shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds receiving allocation as per (a) above. Up to 60% of the QIB Portion (of up to 10,67,200 Equity Shares may be allocated on a discretionary basis to Anchor Investors of which one-third shall be available for allocation to Mutual Funds only, subject to valid Bid received from Mutual Funds at or above the Anchor Investor Allocation Price	Proportionate basis subject to minimum allotment of 1,600 Equity Shares and further allotment in multiples of 1,600 Equity Shares provided that the unsubscribed portion in either of the sub-categories specified in clauses (a) or (b), may be allocated to applicants in the other sub-category of Non-Institutional Investors.	Proportionate basis subject to minimum allotment of 1,600 Equity Shares
Mode of Bidding	Only through the ASBA Process	Through ASBA process only (excluding the UPI Mechanism) except for Anchor Investors	Through ASBA process only (including the UPI Mechanism for a Bid size of up to ₹5.00 lakhs)	Through ASBA process only (including the UPI Mechanism)
Minimum Bid	1,88,800 equity shares	Such number of Equity Shares in multiples of 1600 Equity Shares, such that the Bid Amount exceeds ₹2.00 lakhs	Such number of Equity Shares in multiples of 1,600 Equity Shares, such that the Bid Amount exceeds ₹2.00 lakhs	1,600 Equity Shares and in multiples of 1,600 Equity Shares thereafter, such that the Bid Amount does not exceed ₹2.00 lakhs
Maximum Bid	1,88,800 equity shares	Such number of Equity Shares in multiples of 1,600 Equity Shares not exceeding the size of the Issue (excluding the Anchor Investor Portion), subject to applicable limits under applicable law	Such number of Equity Shares in multiples of 1,600 Equity Shares not exceeding the size of the Issue (excluding the QIB Portion), subject to applicable limits under applicable law	1,600 Equity SharesSuch number of Equity Shares in multiples of 1,600 Equity Shares so that the Bid Amount does not exceed ₹2.00 lakhs
Mode of Allotment	Compulsorily in dematerialized form			
Trading Lot	1,600 Equity Shares, However the Market Maker may accept odd lots if any in the market as required under the SEBI (ICDR) Regulations, 2018.	1,600 Equity Shares and in multiples thereof	1,600 Equity Shares and in multiples thereof	1,600 Equity Shares and in multiples thereof
Who can apply ⁽³⁾⁽⁴⁾		Public financial institutions as specified in section 2(72) of the Companies Act, scheduled commercial banks, mutual funds, FPIs, VCFs, AIFs, FVCIs registered with SEBI, multilateral and bilateral development financial institutions, state industrial development corporation, insurance companies registered with IRDAI, provident funds (subject to applicable law) with certain minimum corpus pension funds (subject to applicable law) with certain minimum corpus of, National Investment Fund set up by the Government of India, the insurance funds set up and managed by army, navy or air force of the Union of India, insurance funds set up and managed by the Department of Posts, India and Systemically Important Non-Banking Financial Companies	Resident Indian individuals, Eligible NRIs, HUFs (in the name of the Karta), companies, corporate bodies, scientific institutions, societies, and trusts and any individuals, corporate bodies and family offices which are re-categorised as category II FPI (as defined in the SEBI FPI Regulations) and registered with SEBI.	Resident Indian individuals, Eligible NRIs and HUFs (in the name of the Karta)
Terms of Payment	In case of Anchor Investors: Full Bid Amount shall be payable by the Anchor Investors at the time of submission of their Bids ⁽⁴⁾ In case of all other Bidders: Full Bid Amount shall be blocked by the SCSBs in the bank account of the ASBA Bidder (other than Anchor Investors) or by the Sponsor Bank through the UPI Mechanism, that is specified in the ASBA Form at the time of submission of the ASBA Form.			

* full subscription in the Issue.

⁽¹⁾ Our Company may, in consultation with the BRLM, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price Anchor Investor Allocation Price.

⁽²⁾ In terms of Rule 19(2) of the SCRR read with Regulation 252 of the SEBI (ICDR) Regulations, 2018 this is an Issue for at least 25% of the post issue paid-up Equity share capital of the Company. This Issue is being made through Book Building Process, wherein allocation to the public shall be as per Regulation 252 of the SEBI (ICDR) Regulations.

⁽³⁾ Subject to valid Bids being received at or above the Issue Price, undersubscription, if any, in any category, except in the QIB Portion, would be allowed to be met with spill-over from any other category or combination of categories of Bidders at the discretion of our Company in consultation with the BRLM and the Stock Exchange, subject to applicable laws.

⁽⁴⁾ Full Bid Amount shall be payable by the Anchor Investors at the time of submission of the Anchor Investor Application Forms provided that any difference between the Anchor Investor Allocation Price and the Anchor Investor Issue Price shall be payable by the Anchor Investor Pay-In Date as indicated in the CAN.

**COMMON BID
REVISION FORM**

AAKAAR MEDICAL TECHNOLOGIES LIMITED - INITIAL PUBLIC OFFER - R

Registered Office: 801, Heritage Plaza, Telli Galli Cross Road, Andheri (East), Mumbai-400069, Maharashtra, India.
Corporate Identity Number: U74900MH2013PLC244717
Contact Person: Anoopkumar Vishwanathan Pillai, Company Secretary and Compliance Officer; Tel: +91 84528 44024
E-mail: companysecretary@akaarmedical.in; Website: www.akaarmedical.in

FOR RESIDENT INDIAN INVESTORS INCLUDING QIBs,
NON-INSTITUTIONAL BIDDERS, RETAIL INDIVIDUAL
BIDDERS AND ELIGIBLE NRIs APPLYING ON A NON-
REPATRIATION BASIS



To,
The Board of Directors
AAKAAR MEDICAL TECHNOLOGIES LIMITED

100% BOOK BUILT OFFER
ISIN : INE1GYP01013

**Bid cum
Application
Form No.**

MEMBERS OF THE SYNDICATE STAMP & CODE	SUB-SYNDICATE MEMBER/ REGISTERED BROKER SCSB/CDP/RTA STAMP & CODE
SUB-BROKER'S / SUB-AGENT'S STAMP & CODE	SCSB BRANCH STAMP & CODE
BANK BRANCH SERIAL NO.	SCSB SERIAL NO.

1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER	
Mr. /Ms./M/s. _____	
Address _____	
_____ Email _____	
Tel. No. (with STD code) / Mobile _____	
2. PAN OF SOLE / FIRST BIDDER	

3. BIDDER'S DEPOSITORY ACCOUNT DETAILS <input type="checkbox"/> NSDL <input type="checkbox"/> CDSL	
For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID	

PLEASE CHANGE MY BID

4. FROM (AS PER LAST BID OR REVISION)																
Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of 1,600 Equity Shares)								Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only) (In Figures Only)							
	(In Figures)								Bid Price							
	8	7	6	5	4	3	2	1	3	2	1	3	2	1	"Cut-off" (Please ✓ tick)	
Option 1																
(OR) Option 2																
(OR) Option 3																

5. TO (REVISED BID) (ONLY RETAIL INDIVIDUAL BIDDERS CAN BID AT "CUT-OFF")																
Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of 1,600 Equity Shares)								Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1/- only) (In Figures Only)							
	(In Figures)								Bid Price							
	8	7	6	5	4	3	2	1	3	2	1	3	2	1	"Cut-off" (Please ✓ tick)	
Option 1																
(OR) Option 2																
(OR) Option 3																

Please note that applications must be made in minimum of 1,600 Equity Shares and further multiples of 1,600 Equity Shares accordingly.

6. PAYMENT DETAILS [IN CAPITAL LETTERS]		PAYMENT OPTION : FULL PAYMENT <input checked="" type="checkbox"/>
Amount Blocked (₹ in figures)	_____	(₹ in words) _____
ASBA Bank A/c No.	_____	
Bank Name & Branch	_____	
UPI ID (Maximum 45 characters)	_____	

I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS BID REVISION FORM, THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT FOR INVESTING IN PUBLIC OFFER ("GID") AND HEREBY AGREE AND CONFIRM THE "BIDDERS' UNDERTAKING" AS GIVEN ALONG WITH THE BID CUM APPLICATION FORM. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM GIVEN OVERLEAF.

7A. SIGNATURE OF SOLE/ FIRST BIDDER	7B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)	MEMBERS OF THE SYNDICATE / SUB - SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA / AGENT STAMP (Acknowledging upload of Bid in Stock Exchange system)
Date : _____, 2025	I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer. 1) _____ 2) _____ 3) _____	

TEAR HERE

AAKAAR MEDICAL TECHNOLOGIES LIMITED	Acknowledgement Slip for Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent	Bid cum Application Form No.
BID REVISION FORM - INITIAL PUBLIC OFFER - R		
DP ID / CL ID	PAN of Sole / First Bidder	
Additional Amount Blocked (₹ in figures)	ASBA Bank A/c No./UPI ID	Stamp & Signature of SCSB Branch
Bank Name & Branch		
Received from Mr./Ms./M/s.		
Telephone / Mobile	Email	

TEAR HERE

AAKAAR MEDICAL TECHNOLOGIES LIMITED	BID REVISION FORM - INITIAL PUBLIC OFFER - R	Stamp & Signature of Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent	Name of Sole / First Bidder
No. of Equity Shares	Option 1 Option 2 Option 3		
Bid Price (₹)			
Additional Amount Blocked (₹ in figures)			
ASBA Bank A/c No. /UPI ID			
Bank Name & Branch			
Important Note : Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected.			

Acknowledgement Slip for Bidder

**Bid cum
Application
Form No.**